MedTrace Logo

Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML

NCT06536010 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-08-02

No results posted yet for this study

Summary

This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML).

The main objectives of the study are to assess the efficacy and safety of the VAG regimen and to explore the synergistic mechanisms of VAG in combating AML.

Conditions

Interventions

DRUG

Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；

VAG in the induction phase of the ND-AML treatment protocol

Sponsors & Collaborators

  • Yang Xiaotian

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-03
Primary Completion
2026-07-31
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06536010 on ClinicalTrials.gov